An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Posaconazole, a Potent Cytochrome P450 3A Inhibitor, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects

Trial Profile

An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Posaconazole, a Potent Cytochrome P450 3A Inhibitor, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Alectinib (Primary) ; Posaconazole (Primary)
  • Indications Aspergillosis; Candidiasis; Chagas disease; Cryptococcosis; Leishmaniasis; Mycoses; Non-small cell lung cancer; Oropharyngeal candidiasis; Phaeohyphomycosis; Trypanosomiasis; Zygomycosis
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 12 Mar 2016 Results from this trial and other two trial (270330, 237396) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 14 Mar 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 10 Feb 2014 As per the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top